- Trials with a EudraCT protocol (7,578)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7,578 result(s) found for: True negative.
Displaying page 1 of 379.
EudraCT Number: 2021-006700-32 | Sponsor Protocol Number: 80013 | Start Date*: 2022-07-13 |
Sponsor Name:Meander Medical Centre | ||
Full Title: A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using submucosal bevacizumab-800CW. | ||
Medical condition: Colon carcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006796-41 | Sponsor Protocol Number: 80117 | Start Date*: 2022-07-13 |
Sponsor Name:Meander Medical Centre | ||
Full Title: A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CW | ||
Medical condition: Colon carcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006570-23 | Sponsor Protocol Number: FAPI-POLMONE-2021 | Start Date*: 2022-03-17 | |||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | |||||||||||||
Full Title: The Role Of The New Promising Oncological Pet/Ct Tracer [68Ga] Ga-Fapi For Staging Lung Cancer: A Preliminary Study | |||||||||||||
Medical condition: suspected / newly diagnosed lung cancer in staging, patients already on a conventional staging diagnostic path (including FDG-PET / standard CT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005140-18 | Sponsor Protocol Number: RAME-01 | Start Date*: 2015-11-12 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI | |||||||||||||
Medical condition: Prostate cancer patients who showed biochemical relapse after surgery or first-line treatment with radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009235-30 | Sponsor Protocol Number: CRO1250 | Start Date*: 2009-12-02 |
Sponsor Name:Imperial College London | ||
Full Title: Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS) | ||
Medical condition: Schizophrenia characterised by persistent negative symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000789-35 | Sponsor Protocol Number: HPTM06/J/05 | Start Date*: 2006-10-06 |
Sponsor Name:INFAI GmbH | ||
Full Title: Two-way Crossover Comparison of the Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal vs. Standard 13C-Urea Breath Test in Helicobacter Pylori Positive and Neg... | ||
Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) without interuption of medication two weeks prior to test. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001369-25 | Sponsor Protocol Number: HPT30/J/17 | Start Date*: 2018-03-19 |
Sponsor Name:INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH | ||
Full Title: The Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia and GERD T... | ||
Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) with one day break of medication instead of two weeks prior to the test | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003485-24 | Sponsor Protocol Number: CXA-PEDS-13-08 | Start Date*: 2014-09-25 | ||||||||||||||||
Sponsor Name:Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic ... | ||||||||||||||||||
Medical condition: This study is designed to assess the PK, safety, and tolerability of a single intravenous dose of ceftolozane/tazobactam in pediatric patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022463-35 | Sponsor Protocol Number: 3.1 | Start Date*: 2011-07-08 |
Sponsor Name:Manchester Mental Health and Social Care Trust | ||
Full Title: The Benefit of Minocycline on Negative Symptoms in Psychosis: Extent and Mechanisms | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005549-17 | Sponsor Protocol Number: FAPI-MN-2020 | Start Date*: 2021-04-21 | |||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | |||||||||||||
Full Title: Role of [68Ga]Ga-FAPI PET/CT in oncological patients with doubtful or inconclusive findings at [18F]F-FDG PET/CT | |||||||||||||
Medical condition: oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT ima... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001417-21 | Sponsor Protocol Number: ITM202004 | Start Date*: 2020-04-12 | |||||||||||
Sponsor Name:Institute of Tropical Medicine | |||||||||||||
Full Title: An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000060-16 | Sponsor Protocol Number: AMIK-04-02 | Start Date*: 2005-05-06 |
Sponsor Name:Aerogen, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pn... | ||
Medical condition: Ventilator associated pneumonia (VAP) caused by gram negative organisms. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003087-70 | Sponsor Protocol Number: PM1125 | Start Date*: 2011-12-02 |
Sponsor Name:Polichem SA | ||
Full Title: Randomized, open-label, controlled study on the efficacy of Ciclopoli® (ciclopirox 8% nail lacquer) versus Loceryl® (amorolfine 5% nail lacquer) on the culture conversion to negative in patients w... | ||
Medical condition: distal subungual onychomycosis without lunula involvement due to fungal nail pathogens (dermatophytes, white yeasts and/or Scopulariopsis spp. and/or Fusarium spp.) affecting at least one big toenail | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008010-39 | Sponsor Protocol Number: HPTM11/J/08 | Start Date*: 2009-04-23 |
Sponsor Name:INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH | ||
Full Title: The Sensivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia Taking Proto... | ||
Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) with one day break of medication instead of two weeks prior to the test | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002838-36 | Sponsor Protocol Number: CIBOMA/2004-01 | Start Date*: 2005-11-30 |
Sponsor Name:COALICIÓN IBEROAMERICANA DE INVESTIGACIÓN EN ONCOLOGÍA MAMARIA (CIBOMA) | ||
Full Title: PHASE IV.III, MULTICENTER, OPEN, RANDOMIZED TREATMENT STUDY TO EVALUATE THE EFFICACY OF MAINTENANCE THERAPY WITH CAPECITABINE (X) AFTER STANDARD ADJUVANT CHEMOTHERAPY IN PATIENTS WITH OPERABLE, HOR... | ||
Medical condition: Patients with operated breast cancer with no metastatic involvement (AJCC, 2002). Patients will be able to participate whether they present axillary node involvement (node positive) or not (node n... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020079-22 | Sponsor Protocol Number: DG40.08 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:STALLERGENES S.A. | |||||||||||||
Full Title: Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diag... | |||||||||||||
Medical condition: Allergy to grass pollen Allergy to birch pollen Allergy to ragweed pollen Allergy to mites | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001048-73 | Sponsor Protocol Number: BAY41-6551/13084 | Start Date*: 2013-07-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati... | |||||||||||||
Medical condition: Gram-negative pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002708-15 | Sponsor Protocol Number: 17972B | Start Date*: 2019-02-01 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia | |||||||||||||
Medical condition: schizophrenia with persistent prominent negative symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) BG (Prematurely Ended) DE (Completed) PL (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000753-30 | Sponsor Protocol Number: PM0259CA219B0 | Start Date*: 2004-11-08 |
Sponsor Name:Pierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament | ||
Full Title: Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer. | ||
Medical condition: Treatment in women with previously untreated HER2 negative metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000074-51 | Sponsor Protocol Number: GBG 39 | Start Date*: 2005-05-03 |
Sponsor Name:GBG Forschungs GmbH | ||
Full Title: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer | ||
Medical condition: patients with HER2 negative metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
